|
1
|
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
|
J Clin Oncol
|
2010
|
3.06
|
|
2
|
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
|
Clin Pharmacol Ther
|
2002
|
1.63
|
|
3
|
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
|
Cancer Chemother Pharmacol
|
2012
|
1.57
|
|
4
|
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
|
J Clin Pharmacol
|
2011
|
1.08
|
|
5
|
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
|
Toxicol Appl Pharmacol
|
2013
|
0.94
|
|
6
|
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
|
Clin Pharmacokinet
|
2013
|
0.93
|
|
7
|
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
|
Curr Drug Metab
|
2012
|
0.90
|
|
8
|
PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
|
Bioanalysis
|
2013
|
0.87
|
|
9
|
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
|
Cancer Chemother Pharmacol
|
2014
|
0.84
|
|
10
|
Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
|
Bioanalysis
|
2013
|
0.82
|
|
11
|
Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic.
|
Bioanalysis
|
2012
|
0.78
|